Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer

{
  "signal_id": "cebb4566-0083-5db6-8f67-5eeaeb42ffa4",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-24T12:54:00+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/johnson--johnson-announces-erleada-apalutamide-treatment-before-and-after-surgery-reduces-risk-of-recurrence-or-death-by-62-versus-surgery-alone-in-high-risk-prostate-cancer-302918654.html",
    "title": "Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer",
    "ticker": "NYSE:JNJ",
    "excerpt": "NEW BRUNSWICK, N.J. , Oct. 24, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy (ADT), given for six months before and after surgery, with radical prostatectomy alone in patients with high-risk localized or locally advanced prostate cancer. The apalutamide plus ADT regimen reduced the risk of disease recurrence or death by 62 percent compared with surgery alone. The regimen also showed a numerical improvement in metastasis-free survival (MFS), with a 51 percent lower risk of metastasis or death. Patients receiving apalutamide plus ADT also went longer before needing subsequent therapy. 1 These substudy findings build on the primary PROTEUS results presented during the plenary session of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and evaluate a remaining clinical question by directly comparing perioperative apalutamide plus ADT with surgery alone, a longstanding standard of care. 1, 2 The new results were presented as a late-breaking abstract in a proffered paper session at the European Society for Medical Oncology (ESMO) Congress 2026 (#LBA53). The accompanying manuscript has been accepted for publication by European Urology. 1 The burden of recurrence in high-risk localized prostate cancer...",
    "product": "ERLEADA",
    "summary": "Johnson & Johnson announced Phase 3 PROTEUS substudy results evaluating the investigational use of ERLEADA (apalutamide) plus androgen deprivation therapy before and after surgery in high-risk prostate cancer.",
    "location": "New Brunswick, New Jersey, United States",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS225644/Johnson-and-Johnson-Logo-v1.jpg?id=OA3037061&p=facebook",
    "confidence": 0.95,
    "product_data": {
      "name": "ERLEADA",
      "full_text": "ERLEADA® (apalutamide)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-24T12:54:00Z",
    "location_data": [
      {
        "city": "New Brunswick",
        "state": "New Jersey",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-10-24",
    "article_sentence": "Johnson & Johnson (NYSE: JNJ ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy (ADT), given for six months before and after surgery, with radical prostatectomy alone in patients with high-risk localized or locally advanced prostate cancer."
  }
}

curl https://signals.autobound.ai/v1/signals/cebb4566-0083-5db6-8f67-5eeaeb42ffa4 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"jnj.com","limit":20}'